Literature DB >> 26230865

Recent progress in melasma pathogenesis.

Ai-Young Lee1.   

Abstract

Melasma is a common skin pigmentation condition. Given therapeutic difficulty as one of the biggest concerns, understanding of the etiology and pathogenesis of melasma becomes essential. UV irradiation, female sex hormones, and inflammatory processes are addressed as triggering factors with genetic predisposition. The mechanism of UV-induced melanogenesis has been extensively investigated as a model system to study melasma pathogenesis. Hitherto, treatment modalities for melasma are similar to other hyperpigmentation disorders. However, individual triggering factors induce a separate pigmentation disease, whose pathogenic mechanisms and clinical phenotypes are different from the ones encountered in melasma. Fortunately, there have been ongoing updates on melasma pathogenesis with regard to major triggering factors. Presence of certain factors working independently of UV exposure and role of dermal factors and microRNAs are being identified as novel discoveries about melasma pathogenesis. In this review, the melasma pathogenesis is reviewed in association with updated and new findings.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  UV; UV exposure-independent factors; dermal factors; estrogen; melasma; microRNAs; pathogenesis

Mesh:

Year:  2015        PMID: 26230865     DOI: 10.1111/pcmr.12404

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  28 in total

1.  Topical Anti-Estrogen Therapy To Treat Melasma.

Authors:  Philip R Cohen
Journal:  J Clin Aesthet Dermatol       Date:  2017-06-01

2.  Sebocytes contribute to melasma onset.

Authors:  Enrica Flori; Arianna Mastrofrancesco; Sarah Mosca; Monica Ottaviani; Stefania Briganti; Giorgia Cardinali; Angela Filoni; Norma Cameli; Marco Zaccarini; Christos C Zouboulis; Mauro Picardo
Journal:  iScience       Date:  2022-02-04

3.  Proteomic study of facial melasma.

Authors:  Luiza Vasconcelos Schaefer; Leticia Gomes de Pontes; Nayara Rodrigues Vieira Cavassan; Lucilene Delazari Dos Santos; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2022-09-10       Impact factor: 2.113

Review 4.  The Function of Autophagy as a Regulator of Melanin Homeostasis.

Authors:  Ki Won Lee; Minju Kim; Si Hyeon Lee; Kwang Dong Kim
Journal:  Cells       Date:  2022-06-30       Impact factor: 7.666

5.  Efficacy and Safety of Using Noninsulated Microneedle Radiofrequency Alone Versus in Combination with Polynucleotides for the Treatment of Melasma: A Pilot Study.

Authors:  Ma Christina B Gulfan; Rungsima Wanitphakdeedecha; Supisara Wongdama; Nuttagarn Jantanapornchai; Chadakan Yan; Sarawalai Rakchart
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-11

6.  Assessment of the effects of skin microneedling as adjuvant therapy for facial melasma: a pilot study.

Authors:  Emerson V A Lima; Mariana Modesto D A Lima; Mauricio Pedreira Paixão; Hélio Amante Miot
Journal:  BMC Dermatol       Date:  2017-11-28

7.  Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma: A randomized, self-controlled, split-face study.

Authors:  Yang Xu; Renyan Ma; Juliandri Juliandri; Xiaoyan Wang; Bai Xu; Daguang Wang; Yan Lu; Bingrong Zhou; Dan Luo
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 8.  A review of laser and light therapy in melasma.

Authors:  M K Trivedi; F C Yang; B K Cho
Journal:  Int J Womens Dermatol       Date:  2017-03-21

Review 9.  microRNAs in the Regulation of Melanogenesis.

Authors:  Yekatsiaryna Hushcha; Irene Blo; Lucia Oton-Gonzalez; Giulia Di Mauro; Fernanda Martini; Mauro Tognon; Monica De Mattei
Journal:  Int J Mol Sci       Date:  2021-06-05       Impact factor: 5.923

10.  Skin Hyperpigmentation in Indian Population: Insights and Best Practice.

Authors:  Stephanie Nouveau; Divya Agrawal; Malavika Kohli; Francoise Bernerd; Namita Misra; Chitra Shivanand Nayak
Journal:  Indian J Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.